Superworth

Illumina forward PE ILMN

Share price divided by analysts' consensus earnings for the next twelve months, since 2007.

Today, Nov 3, 2026
41.5×
10-year median
56.0×
Against its 10-year history
25th
percentile: 0 is its lowest day, 100 its highest
10-year range
16.3× to 494×
Peer median
28.6×

Illumina's forward PE is 41.5× as of Nov 3, 2026.

That is below its ten-year median of 56.0×, lower than on 75% of days in the last ten years.

Over that time it ranged from 16.3× in Apr 2025 to 494× in Dec 2022.

The median for 10 diagnostics and research stocks of a similar size is 28.6×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far39.7×22.6×48.7×
202527.7×16.3×33.9×
202433.5×33.0×134×
2023129×87.5×490×
2022494×147×494×
2021168×72.7×180×
202071.5×56.6×96.3×
201976.9×50.0×76.9×
201854.1×44.1×67.8×
201748.4×44.7×53.4×
201641.3×39.8×64.3×
201560.2×44.9×74.7×
201462.4×55.2×79.8×
201357.7×31.4×57.7×
201236.0×23.0×37.6×
201122.1×19.5×61.8×
201051.3×35.4×51.6×
200935.1×30.6×50.6×
200835.7×27.9×79.4×
200758.4×40.1×74.0×

Against its peers

Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first, today.

Where Illumina ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Illumina

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.